Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc (NASDAQ: MBOT) is a pioneer in micro-robotic medical technologies focused on revolutionizing minimally invasive procedures. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in developing autonomous surgical platforms like the LIBERTY Robotic System and Self-Cleaning Shunt technology.
Discover comprehensive coverage of MBOT's latest press releases, including clinical milestones, regulatory updates, and strategic partnerships. Our curated news collection serves as a centralized resource for tracking advancements in robotic-assisted interventions designed to reduce surgical trauma and improve patient outcomes.
Key updates include developments in patented micro-robotic platforms, financial performance reports, and innovations addressing complex surgical challenges. Bookmark this page to stay informed about MBOT's progress in creating next-generation tools that aim to transform vascular and endoscopic procedures through precision robotics.
Microbot Medical (Nasdaq: MBOT) has announced a registered direct offering for the purchase and sale of 1,566,669 shares at $1.50 per share, totaling approximately $2.35 million in gross proceeds. Concurrently, unregistered series F preferred investment options to purchase up to 3,133,338 shares at the same price will be issued in a private placement. The closing is expected around June 4, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, other IP projects, and general corporate purposes.
Microbot Medical has received FDA approval to start its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System.
The trial will be conducted in the U.S. and will complement preclinical data to support a future 510(k) submission. The company has signed a clinical trial service agreement with a leading academic medical center and is engaging additional centers.
In parallel, Microbot Medical is completing biocompatibility tests required for the IDE application. CEO Harel Gadot expressed confidence in the technology and commitment to achieving regulatory clearance and commercialization.
Microbot Medical Inc. (Nasdaq: MBOT) has announced the successful completion of the first phase of its collaboration with Corewell Health, showcasing the technical capabilities of its LIBERTY® Endovascular Robotic Surgical System. The partnership aims to explore remote endovascular procedures utilizing the LIBERTY System. Led by Dr. Ryan Madder, the collaboration has shown promising results in a pre-clinical study published in the Journal of the American College of Cardiology: Cardiovascular Interventions.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
